About Fareon. A clinical-stage biophysics company.
Backed by science.
Powered by physics.
For decades, brain disorders have been treated primarily with drugs designed to manage symptoms. At Fareon, we believe that the future of brain medicine lies not in chemistry alone, but in harnessing physics to engage the body's own repair and regulatory systems.
Our therapies use precisely calibrated electromagnetic fields to influence cellular repair pathways involved in brain inflammation, mitochondrial function, and neurological recovery, without systemic drug exposure.
By targeting underlying biology, rather than the symptoms alone, Fareon is developing a new category of noninvasive medicine for complex disorders of the brain including both neurological and psychiatric conditions.
A new category of medicine is emerging.
Fareon is defining it.
A visionary team inventing the future of medicine
Advisors & collaborators
A public benefit corporation
Improving human health is written into who we are. It is a purpose we are accountable to, alongside the value we create. As a Delaware public benefit corporation (PBC), this structure is not symbolic. Fareon is legally obligated to pursue a defined public benefit, advancing science and technology to deliver products that improve human health, alongside returns for our investors.
Foundation & philanthropic support
Clinical & institutional partners
Fareon advances science in the open, through peer-reviewed publication, and in partnership with leading academic institutions including Mount Sinai and UCSF. Our earliest work has been supported by mission-aligned philanthropy, including Resonance Philanthropies, the Baszucki Group, and the Zabara Foundation, partners who share our commitment to reaching the patients most in need.